Health Care·Biotechnology·$2.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.94 | N/A | +8.74% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.94 | N/A | +8.74% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management expressed satisfaction with the EPS results, highlighting their commitment to pipeline development. They maintained a cautious outlook without providing specific guidance.
We are pleased with our EPS performance this quarter.
Our focus remains on advancing our pipeline.
IDEAYA Biosciences I reported a narrower-than-expected loss per share, which contributed to a positive stock reaction, rising 1.62%. While there was no revenue data or forward guidance, the management's comments indicated a focus on future developments in their pipeline. Investors may view the EPS beat as a sign of progress, even in the absence of detailed revenue figures.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
PALO ALTO NETWORKS I
Feb 17, 2026